Markets

Insider Trading

Hedge Funds

Retirement

Opinion

5 Best Income Stocks To Invest In

In this article, we discuss 5 best income stocks to invest in. If you want to read our detailed analysis of income stocks and the performance of dividend stocks over the years, go directly to read 14 Best Income Stocks To Invest In

5. Broadcom Inc. (NASDAQ:AVGO)

Number of Hedge Fund Holders: 72

Broadcom Inc. (NASDAQ:AVGO) is an American semiconductor manufacturing company that also specializes in infrastructure software products. Benchmark initiated its coverage on a stock with a Buy rating in April with a $770 price target, highlighting the company’s diverse set of products.

On March 2, Broadcom Inc. (NASDAQ:AVGO) declared a quarterly dividend of $4.60 per share, which was in line with its previous dividend. The company has a 12-year run of raising its dividends consistently, which makes it one of the best dividend stocks on our list. The stock has a dividend yield of 2.96%, as of April 25.

At the end of December 2022, 72 hedge funds tracked by Insider Monkey reported having stakes in Broadcom Inc. (NASDAQ:AVGO), compared with 74 in the previous quarter. The collective value of these stakes is roughly $4 billion.

Aristotle Atlantic Partners, LLC mentioned Broadcom Inc. (NASDAQ:AVGO) in its Q4 2022 investor letter. Here is what the firm has to say:

“Broadcom Inc. (NASDAQ:AVGO) contributed to performance in the quarter following the company’s solid fourth quarter 2022 results. This was driven by better-than-expected results in both its semiconductor solutions, networking and storage segments. The company also provided first quarter guidance that was ahead of consensus as well as 2023 commentary that expects earnings momentum to continue due to a strong product cycle.”

Follow Broadcom Inc. (NASDAQ:AVGO)

4. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 75

Pfizer Inc. (NYSE:PFE) is a New York-based multinational pharmaceutical and biotechnology company. It currently offers a quarterly dividend of $0.41 per share for a dividend yield of 4.17%, as of April 25. The company has been making uninterrupted dividend payments to shareholders for the past 337 quarters with a 13-year streak of consistent dividend growth. The company is among the best dividend stocks on our list.

BofA mentioned Pfizer Inc. (NYSE:PFE) in its April investors’ note and highlighted that the company’s outlook for the year remains to be ‘solid’. The firm maintained a Neutral rating on the stock with a $45 price target.

As per Insider Monkey’s Q4 2022 database, 75 hedge funds were long Pfizer Inc. (NYSE:PFE), owning stakes with a total value of over $2.5 billion.

Diamond Hill Capital mentioned Pfizer Inc. (NYSE:PFE) in its Q3 2022 investor letter. Here is what the firm has to say:

“Also among our bottom contributors were health care products manufacturer Abbott Labs, global pharmaceutical company Pfizer Inc. (NYSE:PFE), media and technology giant Alphabet, and insurance company American International Group (AIG). Although Pfizer continues to report strong performance of its core drugs, sales of its COVID vaccine and treatment have likely peaked and sales are expected to decline going forward. We remain optimistic about the company long term as we believe management is taking the company in the right direction, focusing R&D, and making strategic acquisitions with profits generated from COVID vaccine sales.”

Follow Pfizer Inc (NYSE:PFE)

3. Analog Devices, Inc. (NASDAQ:ADI)

Number of Hedge Fund Holders: 75

Analog Devices, Inc. (NASDAQ:ADI) specializes in semiconductor manufacturing and data conversion. The company has raised its dividend 20 times in the past 19 years, which makes it one of the best dividend stocks on our list. It currently pays a quarterly dividend of $0.86 per share for a dividend yield of 1.90%, as of April 25.

The number of hedge funds tracked by Insider Monkey owning stakes in Analog Devices, Inc. (NASDAQ:ADI) grew to 75 in Q4 2022, from 66 a quarter earlier. These stakes have a collective value of roughly $5 billion.

Giverny Capital mentioned Analog Devices, Inc. (NASDAQ:ADI) in its Q4 2022 investor letter. Here is what the firm has to say:

“Ashtead Group and Analog Devices, Inc. (NASDAQ:ADI) were new purchases, made in May. They both performed well from our original purchase prices and I believe we upgraded the quality of our portfolio by adding them.

We established four new positions during the year, each of about 2%: Analog Devices, Ashtead Group, Floor & Décor, and Installed Building Products. We discussed these in prior letters and I’m pleased to report that Ashtead and Analog were among our best performing positions for the year.”

Follow Analog Devices Inc (NASDAQ:ADI)

2. Merck & Co., Inc. (NYSE:MRK)

Number of Hedge Fund Holders: 77

Merck & Co., Inc. (NYSE:MRK) is a New Jersey-based multinational pharmaceutical company. In April, BofA lifted its price target on the stock to $130 and maintained a Buy rating on the shares, appreciating the company’s plans to acquire Prometheus Biosciences.

Merck & Co., Inc. (NYSE:MRK), one of the best dividend stocks, currently pays a quarterly dividend of $0.73 per share, having raised it by 6% in December 2022. With this dividend hike, the company took its dividend growth streak to 12 years. The stock’s dividend yield on April 25 came in at 2.51%.

At the end of December 2022, 77 hedge funds tracked by Insider Monkey owned stakes in Merck & Co., Inc. (NYSE:MRK), with a total value of over $5 billion. Citadel Investment Group was the company’s largest shareholder in Q4.

Artisan Partners mentioned Merck & Co., Inc. (NYSE:MRK) in its Q4 2022 investor letter. Here is what the firm has to say:

Merck & Co., Inc. (NYSE:MRK) is a provider of health care solutions including prescription medicines, vaccines, biologic therapies, animal health and consumer care products. Shares have benefited from investors seeking safety in areas with less economic and interest rate sensitivity. With about one third of its sales generated by blockbuster oncology drug Keytruda, the key issue for investors is the success of its large R&D pipeline to replace those sales when Keytruda comes off patent in 2028. However, Merck seems to be getting little credit from investors for the 60+ programs it has in clinical development, despite having several solid and large new product opportunities. Additionally, the company’s strong balance sheet and robust free cash flow provide it multiple options for future partnerships and acquisitions, besides return of capital to shareholders via dividends and share repurchases.”

Follow Merck & Co. Inc. (NYSE:MRK)

1. QUALCOMM Incorporated (NASDAQ:QCOM)

Number of Hedge Fund Holders: 82

QUALCOMM Incorporated (NASDAQ:QCOM) is an American multinational semiconductor company, based in California. On March 8, the company declared a 7% hike in its quarterly dividend to $0.80 per share. This marked the company’s 20th consecutive year of dividend growth, which makes it one of the best dividend stocks on our list. The company’s shares boast a yield of 2.81%, as recorded on April 25.

The number of hedge funds tracked by Insider Monkey owning stakes in QUALCOMM Incorporated (NASDAQ:QCOM) grew to 82 in Q4 2022, from 80 in the preceding quarter. The consolidated value of these stakes is roughly $2.4 billion.

Madison Investment Management mentioned QUALCOMM Incorporated (NASDAQ:QCOM) in its Q4 2022 investor letter. Here is what the firm has to say:

QUALCOMM Incorporated (NASDAQ:QCOM) continues to be challenged by headwinds in the smartphone supply chain with an expected decline in units for 2022. Despite solid gains in the Internet of Things and Auto segments, Qualcomm’s dominant business remains the smartphone market. We expect to see stabilization of the smartphone market in 2023, including a recovery in China.”

Follow Qualcomm Inc (NASDAQ:QCOM)

You can also take a look at 10 Cheap Canadian Stocks to Buy and 11 Best Diversified Stocks to Buy Now

Follow Insider Monkey on Twitter

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.